Patents Assigned to Enzo Bochem, Inc.
  • Sphingosine pathway modulating compounds for the treatment of cancers
    Patent number: 10675255
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 9, 2020
    Assignee: Enzo Bochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan